UBS Group AG Boosts Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

UBS Group AG increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) by 13.5% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 103,546 shares of the biotechnology company’s stock after buying an additional 12,329 shares during the period. UBS Group AG owned 0.10% of Arrowhead Pharmaceuticals worth $3,422,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in ARWR. China Universal Asset Management Co. Ltd. bought a new position in Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $33,000. Advisors Asset Management Inc. lifted its position in Arrowhead Pharmaceuticals by 94.6% in the 1st quarter. Advisors Asset Management Inc. now owns 720 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 350 shares in the last quarter. Wipfli Financial Advisors LLC bought a new position in Arrowhead Pharmaceuticals in the 3rd quarter valued at approximately $39,000. Captrust Financial Advisors lifted its position in Arrowhead Pharmaceuticals by 22.4% in the 2nd quarter. Captrust Financial Advisors now owns 1,201 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 220 shares in the last quarter. Finally, Van ECK Associates Corp bought a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter valued at $52,000. Hedge funds and other institutional investors own 65.46% of the company’s stock.

Arrowhead Pharmaceuticals Trading Down 0.2 %

Shares of NASDAQ:ARWR opened at $32.35 on Friday. The company has a market cap of $3.50 billion, a price-to-earnings ratio of -22.01 and a beta of 1.05. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $26.81 and a 12 month high of $51.11. The company has a 50-day moving average price of $34.79 and a 200 day moving average price of $34.61.

Arrowhead Pharmaceuticals (NASDAQ:ARWR – Get Rating) last announced its quarterly earnings data on Monday, February 6th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of $1.14 by ($1.53). The firm had revenue of $62.55 million during the quarter, compared to the consensus estimate of $162.52 million. Arrowhead Pharmaceuticals had a negative return on equity of 34.73% and a negative net margin of 54.31%. The firm’s revenue for the quarter was up 127.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.60) EPS. As a group, equities analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.4 EPS for the current year.

Insiders Place Their Bets

In other Arrowhead Pharmaceuticals news, Director Douglas B. Given sold 875 shares of the firm’s stock in a transaction dated Monday, February 27th. The shares were sold at an average price of $32.62, for a total value of $28,542.50. Following the completion of the sale, the director now owns 13,000 shares of the company’s stock, valued at $424,060. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CFO Kenneth Allen Myszkowski sold 30,625 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Thursday, December 29th. The shares were sold at an average price of $40.00, for a total transaction of $1,225,000.00. Following the completion of the sale, the chief financial officer now owns 336,704 shares of the company’s stock, valued at $13,468,160. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Douglas B. Given sold 875 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Monday, February 27th. The shares were sold at an average price of $32.62, for a total transaction of $28,542.50. Following the sale, the director now directly owns 13,000 shares of the company’s stock, valued at approximately $424,060. The disclosure for this sale can be found here. Insiders sold a total of 91,341 shares of company stock valued at $3,494,172 over the last 90 days. Insiders own 5.00% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on ARWR. SVB Leerink lowered their price target on Arrowhead Pharmaceuticals from $33.00 to $31.00 and set a “market perform” rating on the stock in a report on Tuesday, November 29th. Chardan Capital reissued a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Friday, February 10th. Robert W. Baird lowered their price target on Arrowhead Pharmaceuticals from $60.00 to $58.00 and set an “outperform” rating on the stock in a report on Tuesday, February 7th. Piper Sandler lowered their price target on Arrowhead Pharmaceuticals from $55.00 to $52.00 and set an “overweight” rating on the stock in a report on Tuesday, February 7th. Finally, Royal Bank of Canada lowered their price target on Arrowhead Pharmaceuticals from $83.00 to $77.00 and set an “outperform” rating on the stock in a report on Tuesday, February 7th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.10.

Arrowhead Pharmaceuticals Company Profile

(Get Rating)

Arrowhead Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC.